.png)
Coronavirus Disease 2019 and Gastrointestinal Involvement: A Systematic Review
Abstract
Introduction: The World Health Organization (WHO) announced the Coronavirus 2019 (COVID-19) as a Public Health Emergency of International Concern (PHEIC) toward the end of January 2020. There is still limited evidence to explain the gastrointestinal involvement in COVID-19. In this study, we aimed to further investigate current evidence describing the gastrointestinal involvement in COVID-19 patients.
Methods: This systematic review has been registered in PROSPERO (CRD42020181584). A systematic search of literature for observational and randomized controlled trial was conducted in PubMed, PubMed central, and Google Scholar through April 16, 2020. Two reviewers independently searched and selected. The risk of bias was evaluated using the Newcastle-Ottawa Quality assessment tool.
Results: A total of 1,480 articles were screened from which 12 articles with 5584 subjects were selected. SARS-CoV-2 can invade human body by binding to angiotensin converting enzyme 2 (ACE-2) receptor which also located to small intestinal epithelial cells, crypt cells and colon. The virus itself may cause disorders of the intestinal flora. The diagnosis should be based on a set of symptoms diarrhoea, nausea, vomiting, abdominal discomfort or pain, combined with positivity of faecal PCR test. Treatment of COVID-19 mainly is supportive care. The probiotic may modulate the gut microbiota to alter the gastrointestinal symptoms and reduced enteritis, ventilator associated pneumonia, and reverse certain side effect of antibiotics.
Conclusion: Our synthesis of literature showed that there was no good evidence yet in overall area of gastrointestinal manifestations in COVID-19. Future research is needed to explore all areas, especially in mechanism and treatments
Keywords
DOI: http://dx.doi.org/10.19166/med.v8i2.3443
Full Text:
PDFReferences
1. Kementrian Kesehatan. Pedoman COVID REV-4. Pedoman Pencegah dan Pengendali CORONAVIRUS Dis. 2020.
2. WHO. WHO coronavirus disease 2019 (COVID-19) dashboard. data last update 2021/02/15 4.05 pm CET. Citated on February 15th, 2021. Available from https://covid19.who.int/
3. Yee J, Unger L, Zadravecz F, Cariello P, Seibert A, Johnson MA, et al. Novel coronavirus 2019 (COVID‐19): Emergence and implications for emergency care. J Am Coll Emerg Physicians Open. 2020;(February):1-7.
https://doi.org/10.1002/emp2.12034
4. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7).
https://doi.org/10.1128/JVI.00127-20
5. Wong SH, Lui RN, Sung JJ. Covid-19 and the Digestive System. J Gastroenterol Hepatol. 2020;0-3.
https://doi.org/10.1111/jgh.15047
6. Hindson J. CoVID-19: Faecal Oral Transmission? Nat Rev Gastroenterol Hepatol. 2020;41575.
https://doi.org/10.1038/s41575-020-0295-7
7. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J gastrology. 2020;Pre-proof.
https://doi.org/10.14309/ajg.0000000000000620
8. Kenneth McIntosh M. Coronavirus disease 2019 (COVID-19). Coronavirus Dis 2019 [Internet]. 2020; Available from: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19?search=society-guideline-links-coronavirus-disease-2019&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2%0A
9. Italian Society of Infectious and Tropical Diseases. Guidelines for the treatment of people with COVID-19. 2020;8(March).
10. Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol [Internet]. 2020;2019(20):2019-21.
https://doi.org/10.1016/S2468-1253(20)30076-5
11. Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology [Internet]. 2020.
https://doi.org/10.1053/j.gastro.2020.02.054
12. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected with SARS-CoV-2 in Singapore. JAMA - J Am Med Assoc. 2020;1-7.
https://doi.org/10.1001/jama.2020.3204
13. Health P. COVID-19 Science Report: Diagnostics, NUS Saw Swee Hock School of Public Health As of 30 March 2020. 2020; Available from: https://www.finddx.org/covid-19/pipeline/
14. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-36.
https://doi.org/10.1056/NEJMoa2001191
15. Rahman S, Bahar T. COVID-19: The New Threat. Int J Infect. 2020;7(1):1-6.
https://doi.org/10.5812/iji.102184
16. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;1-13.
https://doi.org/10.1101/2020.02.06.20020974
17. Nidovirales R. 2019nCoV Coronavirus.
18. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA - J Am Med Assoc. 2020;2-3.
https://doi.org/10.1001/jama.2020.3786
19. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chinese Med Assoc. 2020;83(3):217-20.
https://doi.org/10.1097/JCMA.0000000000000270
20. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. WHO - Interim Guid. 2020;2019(January):1-7.
21. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med [Internet]. 2020;46(4):586-90.
https://doi.org/10.1007/s00134-020-05985-9
22. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [published online ahead of print January 30, 2020]. Lancet. https://doi.org/10.1016/S0140-6736(20)30211-7
23. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [published online ahead of print February 7, 2020]. JAMA. https://doi.org/10.1001/jama.2020.1585
24. Fang D, Ma J, Guan J. et al. Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study. Chin J Dig. 2020,40: Epub ahead of print (in Chinese). https://doi.org/10.3760/cma.j.i ssn.0254-1432.2020.0005
25. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020. Published online March 5.
https://doi.org/10.1002/ppul.24718
26. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology [Internet]. 2020;1-3.
https://doi.org/10.1053/j.gastro.2020.02.055
27. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020.
https://doi.org/10.1038/s41591-020-0817-4
28. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Sinto R, et al. Coronavirus Disease 2019 : Tinjauan Literatur Terkini Coronavirus Disease 2019 : Review of Current Literatures. J Penyakit Dalam Indones. 2020;7(1):45-67.
https://doi.org/10.7454/jpdi.v7i1.415
29. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;1-13.
https://doi.org/10.1056/NEJMoa2001282
31. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering [Internet]. 2020.
https://doi.org/10.1016/j.eng.2020.03.007
32. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;19.
https://doi.org/10.1111/all.14238
33. Hariyanto TI, Kristine E, hardi CJ, Kurniawan A. Efficacy of lopinavir/ritonavir compared with standard of care for treatment for Coronavrus Disease 2019 (COVID-19): a systematic review. Infectious Disorders-drug targets. 2020.
https://doi.org/10.2174/1871526520666201029125725
34. Hariyanto TI, kwenandar F, Japar KV, Damay V, Kurniawan A. The effectiveness and safety of remdesivir for the treatment of patients with COVID-19: a systematic revew and Meta-Analysis. Anti-infective agents 2020. https://doi.org/10.2174/2211352518999201009124433
35. Hariyanto T, Japar K, Damay V, Kwenandar F, Sieto N, Kurniawan A. The Use of ACE inhibitor/ARB in SARS-CoV-2 Patients: A Comprehensive Narrative Review. AJMS [Internet]. 1Nov.2020 [cited 8Feb.2021];11(6):113-20. https://doi.org/10.3126/ajms.v11i6.29911
36. Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID_19) infection. Obesity Medicine 2020.
https://doi.org/10.1016/j.obmed.2020.100290
37. Hariyanto TI, Kurniawan A. Statin Therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes and metabolic 6):1613-syndrome: clinical research and reviews. 2020;14(6):1613-5.
https://doi.org/10.1016/j.dsx.2020.08.023
38. Hariyanto TI, Kurniawan A. Anemia is Associated with severe coronavirus disease 2019 (COVID-19) infection. Transfusion and apheresis science 2020. https://doi.org/10.1016/j.transci.2020.102926
39. Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes and metabolic syndrome: Clinical research and reviews. 2020;14(5):1429-30. https://doi.org/10.1016/j.dsx.2020.07.044
40. Lugito NP, Kurniawan A, Damay V, Chyntya H, Sugianto N. The role of gut microbiota in SARS-CoV-2 infection: Focus on angiotensin-converting enzyme 2. Curr Med Issues 2020;18:261-3.
https://doi.org/10.4103/cmi.cmi_80_20
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Moryella Monica, Andree Kurniawan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
MEDICINUS is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Copyright © Fakultas Kedokteran | Universitas Pelita Harapan | Lippo Karawaci, Tangerang, Indonesia, 15811 . All rights reserved. p-ISSN 1978-3094 | e-ISSN 2622-6995